Skip to main content
Clinical Trials/ACTRN12624000696594
ACTRN12624000696594
Recruiting
未知

The effect of reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM).

Sydney Local Health District0 sites313 target enrollmentMay 31, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Cystic Fibrosis
Sponsor
Sydney Local Health District
Enrollment
313
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 31, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Adult (18 years and older) participants with cystic fibrosis
  • 2\.Taking Highly Effective Modulator Therapy (HEMT) for 3 months or longer
  • 3\.Willing to provide informed consent and willing to participate and comply with study requirements.
  • 4\.Enrolled to the Australian Cystic Fibrosis Data Registry

Exclusion Criteria

  • 1\.Exacerbation within the last 28 days
  • 2\.History of hospitalization for CF respiratory exacerbation in the past 12 months
  • 3\.ppFEV1 \< 40% (on HEMT)
  • 4\.Antibiotic treatment for non\-tuberculous mycobacterial disease within the past 28 days
  • 5\.Changes to chronic therapies (for example nebulized therapies, azithromycin) within the past 28 days
  • 6\.Use of an investigational product within the past 28 days
  • 7\.New growth of Pseudomonas, Mycobacterium abscessus and Burkholderia cepacia complex within the past 90 days
  • 8\.Transition from paediatric to adult care within the last 12 months
  • 9\.Women who are pregnant
  • 10\.Prior lung transplant

Outcomes

Primary Outcomes

Not specified

Similar Trials